文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

线粒体损伤在脓毒症诱导血小板活化中的作用

Role of Mitochondrial Impairment in Sepsis-Induced Platelet Activation.
PubMed 文献 · Crit Care Med · 2026-10-21
一句话结论体外实验显示,脓毒症血浆可致人血小板线粒体功能障碍并增强血小板活化,线粒体靶向活性氧清除剂MitoTEMPO可显著逆转这一效应。

该实验室研究纳入脓毒症/脓毒性休克患者(n=3/7)、非脓毒症烧伤患者(n=10)及健康对照(n=10),用患者血浆体外处理健康人血小板及血小板线粒体。脓毒症血浆显著降低血小板基础、最大及ATP相关氧耗率,并降低线粒体复合物I活性,同时增强肾上腺素诱导的血小板活化。预先使用线粒体选择性活性氧清除剂MitoTEMPO可显著逆转上述效应。研究提示线粒体功能障碍参与脓毒症血小板过度活化,可能成为减轻脓毒症器官损伤的新治疗方向。

要点

  • 脓毒症/脓毒性休克患者血浆体外孵育健康人血小板,可显著降低血小板基础、最大及ATP相关氧耗率,提示线粒体呼吸功能受损。
  • 脓毒症血浆孵育血小板线粒体后,复合物I活性较健康血浆及非脓毒症烧伤患者血浆均显著降低。
  • 线粒体功能障碍伴随肾上腺素诱导的血小板活化增强,支持线粒体损伤参与脓毒症血小板过度活化。
  • 预孵育线粒体选择性活性氧清除剂MitoTEMPO可显著逆转脓毒症血浆诱导的线粒体功能障碍及血小板活化增强。
  • 该研究为体外实验,结果仅支持机制探索,不能作为临床使用MitoTEMPO或抗氧化剂的依据。

适用人群与场景

  • 脓毒症/脓毒性休克患者(n=3/7)的血浆用于体外处理健康人血小板及血小板线粒体。
  • 对照组包括非脓毒症烧伤患者(n=10)和健康对照者(n=10)的血浆。
  • 研究场景为大学医院实验室体外研究,不涉及对患者直接干预。

诊断标准与关键阈值

  • 原文未提及脓毒症/脓毒性休克的诊断标准及具体界值。
  • 血小板线粒体功能障碍以血小板氧耗率(基础、最大、ATP相关)和线粒体复合物I活性下降为指标。
  • 血小板活化以肾上腺素诱导的血小板聚集增强为指标。

处置流程与药物剂量

  • 实验干预为体外将健康人血小板及血小板线粒体与脓毒症/脓毒性休克患者血浆共孵育。
  • 干预药物为线粒体选择性活性氧清除剂MitoTEMPO,采用预孵育方式给药;原文未提供具体浓度、剂量、孵育时间及给药途径。
  • 原文未提供适用于临床患者的药物剂量、频次、疗程或目标值。

红旗征与不能漏的情况

  • 原文未提及需要立即处理或不能漏诊的临床红旗征。

研究设计与关键结果

  • 研究类型为实验室研究,单中心,样本为脓毒症/脓毒性休克患者10例、非脓毒症烧伤患者10例、健康对照10例。
  • 脓毒症血浆孵育血小板显著降低基础、最大及ATP相关氧耗率。
  • 脓毒症血浆孵育血小板线粒体降低复合物I活性,与健康血浆及非脓毒症烧伤血浆相比均降低。
  • 复合物I活性降低与肾上腺素诱导的血小板活化增强相关。
  • 预孵育MitoTEMPO可显著逆转脓毒症血浆诱导的线粒体功能障碍及血小板活化增强。

证据类型、等级与局限

  • 证据类型为实验室研究(体外机制研究),非临床研究。

对床旁实践的改变

  • 该研究不改变当前急诊/ICU对脓毒症患者血小板活化或器官功能保护的常规临床处置。
  • 研究仅提供体外机制证据,提示线粒体靶向抗氧化可能成为未来研究方向,但不能作为临床使用MitoTEMPO或其他抗氧化剂的依据。
  • 不适用人群:原文为体外实验,未提供适用于脓毒症患者的临床治疗人群。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Sepsis-induced mitochondrial impairment has been described in different organs, in both animal models and humans. Excessive radical oxygen species (ROS) could be involved in this phenomenon. As a result, antioxidants have been proposed as a potential therapeutic strategy, although results remain controversial. Platelet hyperactivation is considered a central pathogenic mechanism in the development of sepsis-induced organ damage. In this study, we aimed to determine whether mitochondrial dysfunction contributes to platelet hyperactivation during sepsis. We also evaluated the effect of ROS scavenging using the mitochondria-targeted antioxidant MitoTEMPO.

DESIGN: Laboratory investigation.

SETTING: University Hospital.

PATIENTS AND SUBJECTS: Patients with sepsis/septic shock (n = 3/7), nonseptic burn patients (n = 10), and healthy control subjects (n = 10).

INTERVENTIONS: Platelet mitochondria and isolated platelets from healthy donors were treated in vitro with plasma from patients with sepsis/septic shock and healthy subjects, before and after preincubation with MitoTEMPO.

MEASUREMENTS AND MAIN RESULTS: We measured platelet oxygen consumption rates in isolated human platelets using the Seahorse Extracellular Flux Analyzer. Platelet mitochondrial respiratory chain enzyme activity was measured in mitochondria-enriched fractions by spectrophotometry. Platelet aggregation in platelet-rich plasma was analyzed using light-transmission aggregometry, and leukocyte-platelet adhesion in whole blood by flow cytometry.We found that incubating platelets with septic plasma significantly reduced basal, maximal, and adenosine triphosphate-linked oxygen consumption rate. Incubation of platelet mitochondria with septic plasma also reduced platelet Complex I activity, compared with healthy plasma or plasma from nonseptic burn patients. This decrease was associated with an increase in Epinephrine-induced platelet activation. Preincubating platelets with the mitochondria-selective ROS scavenger MitoTEMPO significantly reversed these effects.

CONCLUSIONS: Our results show that the mitochondria-selective ROS scavenger MitoTEMPO prevents mitochondrial dysfunction and enhances platelet activation induced by septic plasma in human platelets in vitro. This may help in designing new therapeutic approaches to prevent sepsis-induced organ damage mediated by mitochondrial dysfunction and platelet hyperactivation.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Greco, Schiavello, Bosco, et al. Role of Mitochondrial Impairment in Sepsis-Induced Platelet Activation. Crit Care Med. 2026. PMID: 42925135. doi:10.1097/CCM.0000000000007407

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。